Literature DB >> 23231029

Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.

Weiwei Xue1, Xiaojie Jin, Lulu Ning, Meixia Wang, Huanxiang Liu, Xiaojun Yao.   

Abstract

The rapid emergence of cross-resistance to the integrase strand transfer inhibitors (INSTIs) has become a serious problem in the therapy of human immunodeficiency virus type 1 (HIV-1) infection. Understanding the detailed molecular mechanism of INSTIs cross-resistance is therefore critical for the development of new effective therapy against cross-resistance. On the basis of the homology modeling constructed structure of tetrameric HIV-1 intasome, the detailed molecular mechanism of the cross-resistance mutation E138K/Q148K to three important INSTIs (Raltegravir (RAL, FDA approved in 2007), Elvitegravir (EVG, FDA approved in 2012), and Dolutegravir (DTG, phase III clinical trials)) was investigated by using molecular dynamics (MD) simulation and residue interaction network (RIN) analysis. The results from conformation analysis and binding free energy calculation can provide some useful information about the detailed binding mode and cross-resistance mechanism for the three INSTIs to HIV-1 intasome. Binding free energy decomposition analysis revealed that Pro145 residue in the 140s 1oop (Gly140 to Gly149) of the HIV-1 intasome had strong hydrophobic interactions with INSTIs and played an important role in the binding of INSTIs to HIV-1 intasome active site. A systematic comparison and analysis of the RIN proves that the communications between the residues in the resistance mutant is increased when compared with that of the wild-type HIV-1 intasome. Further analysis indicates that residue Pro145 may play an important role and is relevant to the structure rearrangement in HIV-1 intasome active site. In addition, the chelating ability of the oxygen atoms in INSTIs (e.g., RAL and EVG) to Mg(2+) in the active site of the mutated intasome was reduced due to this conformational change and is also responsible for the cross-resistance mechanism. Notably, the cross-resistance mechanism we proposed could give some important information for the future rational design of novel INSTIs overcoming cross-resistance. Furthermore, the combination use of molecular dynamics simulation and residue interaction network analysis can be generally applicable to investigate drug resistance mechanism for other biomolecular systems.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23231029     DOI: 10.1021/ci300541c

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  15 in total

Review 1.  Anti-HIV drug development through computational methods.

Authors:  Wan-Gang Gu; Xuan Zhang; Jun-Fa Yuan
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

2.  The conformational feasibility for the formation of reaching dimer in ASV and HIV integrase: a molecular dynamics study.

Authors:  Sangeetha Balasubramanian; Muthukumaran Rajagopalan; Ravi Shankar Bojja; Anna Marie Skalka; Mark D Andrake; Amutha Ramaswamy
Journal:  J Biomol Struct Dyn       Date:  2016-11-28

Review 3.  A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.

Authors:  Alexa Vyain Zhao; Rustin D Crutchley; Rakesh Chowdary Guduru; Kathy Ton; Tammie Lam; Amy Cheng Min
Journal:  Retrovirology       Date:  2022-10-22       Impact factor: 3.768

Review 4.  Will drug resistance against dolutegravir in initial therapy ever occur?

Authors:  Mark A Wainberg; Ying-Shan Han
Journal:  Front Pharmacol       Date:  2015-04-29       Impact factor: 5.810

Review 5.  HIV-1 resistance to dolutegravir: update and new insights.

Authors:  Mark A Wainberg; Ying-Shan Han
Journal:  J Virus Erad       Date:  2015-01-01

6.  Dynamic residue interaction network analysis of the oseltamivir binding site of N1 neuraminidase and its H274Y mutation site conferring drug resistance in influenza A virus.

Authors:  Mohini Yadav; Manabu Igarashi; Norifumi Yamamoto
Journal:  PeerJ       Date:  2021-06-02       Impact factor: 2.984

7.  Molecular modeling study on the allosteric inhibition mechanism of HIV-1 integrase by LEDGF/p75 binding site inhibitors.

Authors:  Weiwei Xue; Huanxiang Liu; Xiaojun Yao
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

8.  Lead screening for HIV-1 integrase (IN) inhibited by traditional Chinese medicine.

Authors:  Tzu-Chieh Hung; Wen-Yuan Lee; Kuen-Bao Chen; Yueh-Chiu Chan; Calvin Yu-Chian Chen
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

9.  P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape.

Authors:  Huiyong Sun; Youyong Li; Sheng Tian; Junmei Wang; Tingjun Hou
Journal:  PLoS Comput Biol       Date:  2014-07-17       Impact factor: 4.475

10.  Comparison of Newly Assembled Full Length HIV-1 Integrase With Prototype Foamy Virus Integrase: Structure-Function Prospective.

Authors:  Mohammad Reza Dayer
Journal:  Jundishapur J Microbiol       Date:  2016-02-15       Impact factor: 0.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.